Master Athletes Still Don’t Fully Escape Inflammaging

Decades of training can lower the inflammatory burden of aging. They do not appear to return it to a young-adult baseline. That is the useful, slightly humbling lesson from master athletes: people who have spent years or decades training consistently have a better circulating inflammatory profile than sedentary adults their age, yet they still retain evidence of age-related low-grade inflammation.

A 2025 systematic review and meta-analysis by Pérez-Castillo et al. compared master athletes with sedentary older adults and untrained younger adults. Its directional conclusion was consistent: lifelong exercisers had lower proinflammatory markers than sedentary peers, with C-reactive protein (CRP) the most consistently improved marker. But their profiles did not fully match those of younger adults. Exercise mitigates inflammaging; it has not been shown to erase it.

That distinction matters because chronic low-grade inflammation tracks with real health risk. The review cites a meta-analysis of 14 studies involving 83,995 people in which the highest versus lowest CRP category was associated with a 75% higher risk of death from any cause. This does not mean that lowering one person's CRP through exercise will reduce that person's mortality risk by 75%. It does mean CRP is more than decorative lab-work confetti, and a lower inflammatory profile may matter even if it is incomplete.

Master athletes sit between sedentary aging and youth

Inflammaging describes persistently elevated inflammatory signaling with age, often measured through CRP, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), when there is no acute infection or injury. The master-athlete findings place lifelong training in the middle of a three-part hierarchy: better than sedentary aging, but not equivalent to untrained youth.

The evidence is persuasive about direction, not precision. The published synthesis supports lower proinflammatory circulating markers in master athletes than in sedentary older adults and incomplete normalization against younger adults. However, the available reporting does not provide verified standardized mean differences, confidence intervals, or heterogeneity statistics for each biomarker. Readers should resist turning this result into a fake-exact claim such as "lifelong training lowers IL-6 by X percent." The current evidence does not support that number.

It also does not prove that exercise alone caused the difference. Most master-athlete comparisons are cross-sectional. Athletes who remain healthy enough to train for decades may start with advantages that help them stay active: lower baseline inflammatory tone, fewer injuries, lower body fat, healthier diets, less smoking, or some combination. This healthy-survivor effect can make lifelong exercise look more potent than a population-wide prescription would produce.

Those caveats do not make the comparison useless. They define what it can answer. Master athletes show what is associated with a lifetime of sustained exercise and the lifestyle pattern that often accompanies it. They do not provide a randomized test of whether assigning a broad population to decades of training would produce the same biomarker profile.

Why IL-6 can confuse the picture

IL-6 is a poor candidate for a simple "lower is always better" scorecard. Adipose tissue can release IL-6 as part of a proinflammatory state, especially alongside visceral fat. Contracting skeletal muscle also releases IL-6 during exercise, where it can trigger downstream anti-inflammatory signaling, including increased IL-10. The 2026 meta-analytic compendium on exercise adaptations in aging supports this broader view of exercise as a modifier of several inflammatory and metabolic pathways rather than a single-cytokine switch.

A lower resting IL-6 level in an athlete may therefore reflect lower visceral adiposity, a training-related immune adaptation, or both. A temporary rise in IL-6 during exercise may reflect muscle signaling rather than chronic inflammatory disease. A blood draw without context cannot reliably separate those sources. Resting cytokines are useful markers, but they are not a full mechanistic map.

Training gains require maintenance

The practical point is less glamorous than a biohacking protocol: the anti-inflammatory phenotype associated with training is maintained, not banked. Pérez-Castillo et al. report that short-term detraining can substantially reverse anti-inflammatory gains, with IL-6 specifically identified as a marker that rebounds after exercise stops.

The evidence does not establish a precise timetable for that reversal, its magnitude, or the minimum amount of exercise needed to prevent it. Claims that inflammation rebounds after a particular number of days or weeks would go beyond the available data. Still, the direction of the finding changes the story. Past fitness is valuable, but it is not an inflammatory savings account that pays interest while you stop moving.

More intensity is not automatically better for immune aging

One randomized trial adds an important wrinkle. In Niemiro et al.'s 2022 trial, older women at elevated breast-cancer risk completed aerobic training at either moderate or high intensity. Moderate-intensity exercise significantly reduced peripheral effector-memory and senescent T-cell populations associated with immunosenescence. High-intensity aerobic exercise did not produce those significant reductions.

This was a result in a specific population and measured immune-cell phenotypes rather than clinical disease, mortality, or the master-athlete inflammatory profile. It cannot tell us that hard training harms immune aging, nor can it establish the ideal program for healthy older men and women. It does show that intensity is not merely a volume knob. The immune outcome differed even when both interventions involved aerobic exercise.

That result fits a wider pattern of outcome-specific responses to exercise dose. A meta-analysis comparing high-intensity interval exercise with moderate-intensity continuous training found that intensity can produce different cardiometabolic effects across health and disease. It does not prove that moderate training is universally superior. It argues against treating maximum intensity as a universal anti-aging setting.

What randomized evidence can and cannot add

Randomized studies provide a cleaner test of shorter-term interventions than master-athlete cohorts can. A 2025 systematic review of randomized trials of exercise and protein intake found that exercise can act as an anti-inflammatory intervention in aging populations, while also raising the possibility that nutrition modifies the outcome. A separate 2024 meta-analysis of combined aerobic and resistance training in sedentary adults reported improvements in inflammatory markers and adipokine profiles across 24 randomized trials.

These trials strengthen the case that exercise can change inflammatory biomarkers. They do not solve the decades-long question. Short interventions cannot show whether benefits keep accumulating, plateau, or fade over a lifetime. They also cannot fully answer how much of the master-athlete advantage comes from exercise itself versus lower body fat, diet, and other behaviors that travel with sustained training.

Animal studies make the mechanism less tidy

Preclinical work offers a partial parallel, not a clean proof. The Pérez-Castillo review describes one lifelong wheel-running study in older rodents in which trained animals had higher circulating IL-10 than sedentary animals, while IL-6 and high-sensitivity CRP were similar between groups. Another rodent study found no association between lifelong exercise and inflammatory markers.

Those findings are compatible with the human pattern: exercise may improve some anti-inflammatory signaling without fully normalizing every proinflammatory marker. But the studies disagree, and rodents do not settle the human mechanism. Controlled animal work reduces some confounding; it does not eliminate differences in strain, exercise behavior, measurement, or relevance to human aging.

The useful verdict

Lifelong exercise remains one of the strongest behavioral tools available for reducing the inflammatory burden associated with aging. The master-athlete evidence makes the case without promising a miracle: compared with sedentary peers, lifelong exercisers have a more favorable proinflammatory profile. The same evidence shows a residual gap from young-adult levels and suggests that stopping training can reverse gains.

• Train for continuity. The benefit appears to depend on continued activity, not a heroic training block years ago.
• Keep meaningful moderate-intensity work in the program. The Niemiro trial found immune-cell benefits at moderate, not high, aerobic intensity.
• Manage body composition and diet alongside exercise. Lower visceral fat may explain part of the CRP and resting IL-6 advantage, and protein intake may modify inflammaging outcomes.
• Use CRP and cytokines cautiously. They are biomarkers, not direct proof that one intervention has reset biological age.

Master athletes offer a demanding but realistic benchmark: sustained exercise can make aging biologically better than sedentary aging. It has not been shown to make aging disappear.